Skip to main content

SYNERGY™ XD

Everolimus-Eluting Platinum Chromium Coronary Stent System

play icon
Introducing SYNERGY XD
The SYNERGY XD BP Stent
FIRST and ONLY 48 mm DES in the U.S.
The first DES indicated for use in High Bleeding Risk patients*
synchronous drug elution and polymer absorption
play icon
Introducing SYNERGY XD
The SYNERGY XD BP Stent
FIRST and ONLY 48 mm DES in the U.S.
The first DES indicated for use in High Bleeding Risk patients*
synchronous drug elution and polymer absorption
Introducing SYNERGY XD
The SYNERGY XD BP Stent features an innovative delivery system for Xtra Deliverability.
Size matrix includes the FIRST and ONLY 48 mm DES in the U.S.
The first DES indicated for use in High Bleeding Risk patients*
Unlike permanent polymer DES technology, the SYNERGY XD BP Stent features synchronous drug elution and polymer absorption for optimal healing.

Delivering More.

Xtra Deliverability. Optimal Healing.

Introducing the next generation SYNERGY Bioabsorbable Polymer (BP) Stent. The SYNERGY XD Stent System is equipped with a delivery system designed to make optimal healing even more deliverable.

Receive Updates
icon_document.png

Directions for Use

 icon_document.png

Indications, Safety, and Warnings

 icon_computer.png

Modern PCI Treat Portfolio

Explore

 

Visibility

 

Why Visibility is Important

Good visualization is key for accurate placement and optimal outcomes. Stent misplacement at the ostium occurs frequently and is associated with higher rates of restenosis and target lesion revascularization (TLR).*

SYNERGY Visibility Pie Chart
True ostium was missed in 54% of cases.*
 

See the difference

Even with thin struts, the high density of Platinum Chromium allows for greater visibility.†

 
SYNERGY Visibility Chart
 

* “High Incidence of Inaccurate Stent Placement in the Treatment of Coronary Aorto-Ostial disease” : https://www.invasivecardiology.com/articles/high-incidence-inaccurate-stent-placement-treatment-coronary-aorto-ostial-disease
† Testing Completed by Boston Scientific data on file. 2.5 mm stent products tested. Based on 2.5mm stents. Under 6.0mm copper phantom to simulate body mass. Bench test results may not necessarily be indicative of clinical performance.

 

Xtra Deliverability

 

Innovative Delivery System

The SYNERGY XD BP Stent System combines added trackability and pushability with a low-profile stent platform to enable better navigation of challenging anatomy.‡

 
Xtra Deliverability

‡ Based on bench testing of SYNERGY and SYNERGY XD BP Stents. Radial Guide Tracking and Radial Push Transmission; 3.00 mm stent systems tested, n=15 units. Bench testing performed by Boston Scientific. Results not necessarily indicative of clinical performance.

 

SYNERGY XD 48 mm

 

FIRST and ONLY 48 mm DES in the U.S.

Designed for Complex Cases

  • Excellent Conformability
  • Exceptional Overexpansion up to 5.75 mm§

    •  

Procedural Efficiency

  • Reduced Treatment Cost
  • Reduced Procedure Time
  • Reduced Radiation Exposure and Contrast1
 

Quality Outcomes for Patients

1-year results from the EVOLVE 48 Trial support the safety and effectiveness of the SYNERGY XD 48 mm BP Stent for the treatment of long lesions**2

Learn More
Quality Outcomes for Patients, SYNERGY XD product shot

§ The labeled dilation limit of the 4.00 - 5.00 mm stent diameters is 5.75 mm. Please see the SYNERGY XD DFU for dilation limits for all diameters.
** Clinical data conducted with SYNERGY 48 mm, SYNERGY XD’s predecessor device, which can be used to illustrate SYNERGY XD 48 mm clinical data.

 

Studying DAPT

The First DES Indicated for Use in High Bleeding Risk Patients††

The SYNERGY BP Stent can be safely used in conjunction with shortened DAPT in patients at high risk for bleeding (HBR), based on the results from the EVOLVE Short DAPT Trial. This trial data in conjunction with the HBR indication, provides important evidence to inform decisions about DAPT duration for this patient subset.

 


HIGH BLEEDING RISK INDICATION, SYNERGY XD Stent

EVOLVE Short DAPT Trial ‡‡³

Studying 3-month DAPT in high bleeding risk patients
Learn More
 

†† in the US. The HBR indication excludes the SYNERGY XD 48 mm stent.
‡‡ EVOLVE Short DAPT is a prospective, multicenter, single-arm trial defining the safety of 3-month DAPT in subjects at high risk for bleeding undergoing PCI with the SYNERGY BP Stent. Approximately 74% of patients enrolled discontinued DAPT at 3-months. N=1,396 (patients with respective event or sufficient follow-up). Co-primary endpoints: ARC Def/Prob ST and Death/MI from 3-15 months. High risk bleeding subjects were defined as meeting one or more of the following criteria: ≥75 years of age and, in the opinion of the investigator, the risk of bleeding associated with >3 months of DAPT outweighs the benefit; need for chronic or lifelong anticoagulation, history of major bleeding (severe/ life threatening or moderate bleeding based on the GUSTO classification) within 12 months of the index procedure; history of stroke (ischemic or hemorrhagic); renal insufficiency (creatinine ≥2.0 mg/dl) or failure (dialysis dependent); platelet count ≤100,000/μL.

 

Optimal Healing

Fast Absorbing Bioabsorbable Polymer Advantage

Unlike permanent polymer DES technology, the SYNERGY XD Bioabsorbable Polymer is gone shortly after the drug is completely eluted.4

Optimal Healing, SYNERGY XD

Trusted Everolimus Drug

Optimized drug elution to be synchronous with polymer absorption

 

Abluminal Polymer Application

Suppresses neointimal growth while promoting early healing

 

Thin, Rounded Struts

Stents with thinner struts heal faster than thicker stent struts5

 
 

Ordering Information

 

Stent Length (mm)

ø 

(mm)

 8 12 16 20 24 28 32 38 48

Expansion

Limit
2.25  H7493941808220  H7493941812220  H7493941816220  H7493941820220  H7493941824220  H7493941828220  H7493941832220  H7493941838220    3.50
2.50  H7493941808250  H7493941812250  H7493941816250  H7493941820250  H7493941824250  H7493941828250 H7493941832250  H7493941838250  H7493941848250 3.50
2.75 H7493941808270  H7493941812270  H7493941816270  H7493941820270 H7493941824270  H7493941828270  H7493941832270  H7493941838270  H7493941848270 3.50
3.00 H7493941808300  H7493941812300  H7493941816300  H7493941820300  H7493941824300  H7493941828300  H7493941832300  H7493941838300  H7493941848300 4.25
3.50 H7493941808350  H7493941812350  H7493941816350  H7493941820350  H7493941824350  H7493941828350  H7493941832350  H7493941838350  H7493941848350 4.25
4.0 H7493941808400 H7493941812400 H7493941816400 H7493941820400 H7493941824400 H7493941828400 H7493941832400 H7493941838400 H7493941848400 5.75
4.5   H7493941812450 H7493941816450 H7493941820450 H7493941824450 H749 3941828450 H7493941832450     5.75
5.0   H7493941812500 H7493941816500 H7493941820500 H7493941824500 H7493941828500 H7493941832500     5.75
 
 
Xtra Deliverability

Xtra Deliverability

Learn about the continued advancement in deliverability that SYNERGY XD offers

Button
SYNERGY XD 48 mm

SYNERGY XD 48 mm

Discover the FIRST and ONLY 48 mm DES available in the U.S.

Button
Optimal Healing

Optimal Healing

Find out how synchronous drug elution and polymer absorption enables early healing

Button
 
 
MPCI banner
 
Top